Boston Scientific’s Stent Sales Fall
Boston Scientific Corp. said fourth-quarter sales of its Taxus drug-coated stent fell nearly 12 percent from the previous quarter, but the medical device maker expects the slumping stent market to rebound from recent safety worries.